SBP has the scientific expertise and technology platforms necessary to develop new therapeutics that address unmet clinical needs of patients. Our journey starts at the beginning – establishing innovative disease targets – and continues until our drug therapies are ready for patient testing.
Our Drug Discovery Groups
The Institute’s Cancer Center is one of only seven NCI-designated basic cancer research centers in the nation. We couple fundamental biological research with early translational studies to find new, innovative therapies that restore hope to cancer patients and their families.
The Center for Metabolic Origins of Disease studies common diseases that have reached pandemic scale including obesity, type 2 diabetes and cardiovascular complications. We have established an exciting environment that promotes multi-disciplinary discovery research toward breakthrough preventive and therapeutic strategies.
Infectious diseases such as HIV/AIDS and tuberculosis continue to rank high among global mortality factors, especially in developing countries, and systemic inflammation has been identified as a root case of many chronic disorders in the developed world.
|A drug discovery pipeline is created in distinct stages. At SBP, we start at the beginning—establishing innovative disease targets—and continue until it’s time to test drugs in patients. At that point, we partner with organizations such as hospitals, clinical research organizations and pharmaceutical companies to conduct clinical trials in phases designed to answer specific research questions.|